A Novel Expression Signature from the Perspective of Mesenchymal-Epithelial Transition for Hepatocellular Carcinoma with Regard to Prognosis, Clinicopathological Features, Immune Cell Infiltration, Chemotherapeutic Efficacy, and Immunosuppressive Molecules

<div>The relationship between this signature and chemotherapeutic efficacy and ICIs-related molecules. (a) Low-risk group having a higher IC50 of cisplatin, doxorubicin, and mitomycin and a lower IC50 of sorafenib. (b) High-risk group positively related with PDCD1, CD274, CTLA4, HAVCR2, and LAG3.</div>

Journal of Oncology

fig4

Figure 4

Figure 4: A Novel Expression Signature from the Perspective of Mesenchymal-Epithelial Transition for Hepatocellular Carcinoma with Regard to Prognosis, Clinicopathological Features, Immune Cell Infiltration, Chemotherapeutic Efficacy, and Immunosuppressive Molecules 

Figure 4 | A Novel Expression Signature from the Perspective of Mesenchymal-Epithelial Transition for Hepatocellular Carcinoma with Regard to Prognosis, Clinicopathological Features, Immune Cell Infiltration, Chemotherapeutic Efficacy, and Immunosuppressive Molecules 